NCT07486141 · ACTIVE NOT RECRUITING
Effect of Vitamin D and Folic Acid on Mild Cognitive Impairment
This trial tests whether vitamin D3 plus folic acid, taken daily for six months, can improve or slow the decline of thinking skills in people aged 50 to 70 with mild cognitive impairment. Participants get a lower dose, a higher dose, or a placebo. It has no formal phase, so it is a supplement study, not a drug approval trial.
You may qualify if
- Aged 50 to 70 years old.
- Derived from the established elderly chronic disease and health cohort.
- Meet the diagnostic criteria for Mild Cognitive Impairment (MCI) (e.g., indicated by specific cut-off scores on the MoCA adjusted for education level).
- Volunteered to participate, able to cooperate with the cognitive assessments, and signed the informed consent form.
You're excluded if
- Diagnosis of Alzheimer's disease, other types of dementia, or severe psychiatric disorders (e.g., severe depression, schizophrenia).
- History of severe neurological diseases (e.g., stroke, brain tumor, brain trauma) that may affect cognitive function.
- Severe visual or hearing impairments that prevent the completion of cognitive tests.
- Patients with liver diseases (e.g., hepatitis, liver cirrhosis) or kidney diseases (e.g., nephritis, kidney stones, renal failure).
- Patients with hypercalcemia (serum calcium concentration > 10.5 mg/dl).
- Patients with severe anemia, severe malnutrition, or abnormal thyroid function.
- Current use or use within the past 3 months of cognition-improving drugs, Vitamin D, or Folic Acid supplements, and unwilling to undergo a 3-month washout period prior to the intervention.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-03-20